GlassScriptPhysician profile
Terri Jaggers
NPI 1336158658
$1,905.63
in general payments reported to CMS, 2019-2025
21 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $134 · 2021: $466 · 2022: $285 · 2023: $310 · 2024: $326 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $757.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $653.01 | 2019-2023 | |
| Steris Corporation | $257.45 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $216.91 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $189.19 | 2021-2024 | Entyvio |
| Janssen Biotech, INC. | $169.16 | 2019-2025 | Tremfya |
| Erbe USA INC | $100.00 | 2019 | |
| Ironwood Pharmaceuticals, INC | $40.50 | 2019-2022 | |
| Pfizer INC. | $35.70 | 2023-2025 | |
| Intra-Sana Laboratories | $31.26 | 2021-2022 | |
| Amgen INC. | $27.92 | 2021 | |
| Nestle Healthcare Nutrition INC. | $26.69 | 2021 | |
| Ferring Pharmaceuticals INC. | $19.10 | 2023 | Rebyota |
| Medtronic, INC. | $18.27 | 2024 | Endoflip |
| Gilead Sciences, INC. | $17.67 | 2021 | |
| Ucb, INC. | $16.64 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $15.46 | 2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $15.34 | 2023 | Ocaliva |
| Endogastric Solutions, INC | $15.31 | 2022 | |
| Ardelyx, INC. | $14.05 | 2024 | Ibsrela |
| Olympus America INC. | $13.05 | 2023 | Endoclot Phs |
| Daiichi Sankyo INC. | $12.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terri Jaggers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.